## Congress let the NIH drop the HIV/AIDS set-aside: Implications for NIDA?

Dec 15 2015 Published by under Drug Abuse Science, NIH, NIH Budgets and Economics

Jocelyn Kaiser reported in Science Insider:

the National Institutes of Health (NIH) today announced it will no longer support setting aside a fixed 10% of its budget—or $3 billion this year—to fund research on the disease. The agency also plans to reprogram$65 million of its AIDS research grant funding this year to focus more sharply on ending the epidemic.

Whoa. Big news. This is an old Congressional mandate so presumably it needs Congress to be on board. More from Kaiser:

The changes follow growing pressure in Congress and from some advocacy groups for NIH to reallocate its funding based on the public health burden a disease causes.... some patient groups and members of Congress have recently asked why AIDS receives disproportionately far more than diseases with higher death rates, such as heart disease and Alzheimer’s....Last year, Congress omitted instructions asking NIH to maintain the 10% AIDS set aside.

Emphasis added. An act by omission is good enough for gov'mint work, eh? Congress is on board.

@jocelynkaiser was kind enough to link to relevant NIH budgetary distributions:

As you can see, NIDA devotes about $300M to HIV/AIDS research. The annual NIDA budget allocation is about$1B so you can see that something on the order of 30% of the NIDA budget is (and has been) devoted to this Congressional Mandate.

Wait, whut? What about that 10% mandate above? Yep, the HIV/AIDS money has not been evenly distributed across the ICs.

Now, I don't know exactly when and how all of this shook down. It was FY 1987 when the NIAID budget went up by something like 47% when other similarly sized ICs didn't see such a large percentile increase. Clearly 1986 was when Congress got serious about HIV/AIDS research. We can't assess the meaning of

AIDS has received 10% of NIH’s overall budget since the early 1990s, when Congress and NIH informally agreed it should grow in step with NIH’s overall budget.
...
NIH must treat AIDS dollars as a distinct pot of money within its overall budget. That is because a 1993 law carved out a separate HIV/AIDS budget, Collins says. And undoing that law would take action by Congress.

from this article. It is a little frustrating, to be frank. But...on to the NIDA situation.

NIDA doesn't appear in the NIH tables until FY1993 because it didn't actually join the NIH until 1992. Nevertheless that history page on NIDA notes:

1986: The dual epidemics of drug abuse and HIV/AIDS are recognized by Congress and the Administration, resulting in a quadrupling of NIDA funding for research on both major diseases.

There are many ways of looking at this situation.

Some in the NIDA world who are not all that interested in HIV/AIDS matters complain bitterly about why "A third of our budget is reserved for HIV/AIDS". Our.

Another way of looking at this would be "If Congress mandated NIH devote 10% of its budget to HIV/AIDS but NIH did this by incorporating NIDA with its existing HIV/AIDS funding then the entire rest of NIH is shirking its response to the mandate on the back of NIDA".

And yet a final way of looking at this* would be "Dude, NIDA wouldn't even have this money if not for Congress' interest in funding HIV/AIDS research so it isn't 'our' funding being diverted to HIV/AIDS research."

Is this important? Yes and no.

The news is potentially huge for those who seek to get the HIV/AIDS funding via NIDA grants and for those who seek non-HIV/AIDS funding. It makes matters slightly better for the latter and worse for the former. Right? If there is no special set-aside, the latter folks now have at least a shot at that $300M that had been out of reach for them. This consequently increases the competition for those who have HIV/AIDS relevant proposals. Who are presumably sad right now. But it all depends on what Collins plans to do with his newly won freedom. Back to Kaiser: Francis Collins agrees: At a meeting of his Advisory Committee to the Director (ACD) today, he noted that no other disease receives a set proportion of the NIH budget and the argument that AIDS still deserves such a set-aside is “not a defensible one.” The end of the set-aside has “free[d] us up” to refocus NIH’s AIDs portfolio, Collins says. However the article only then talks about$65M being reprioritized. What about the rest of the 10% of the ~$30B / yr NIH budget? No idea. So I want to know a few things. Is the$300M in the NIDA budget that goes to HIV/AIDS part of this 10% overall NIH mandate? If so, will Collins try to claw that back for some other agenda?

If a miracle occurs and it stays within NIDA, will Nora Volkow use this new-found freedom to ease the pressure on the non-HIV/AIDS researchers by letting them (ok, "us") get a shot at that previously-sequestered pool?

Or will Volkow use it to pay for the latest boondoggle initiatives of ABCD and BRAINI?

The way I hear it, this latter is likely to happen because up to this point all other NIDA initiatives are being squeezed** to make ABCD and BRAINI happen.

Obviously I would prefer to see Volkow choose to use this new freedom a little more democratically by spreading the love across all of the portfolio.

__
*this has been my view for some time now.

**this manifests, IME, as profound pessimism on the part of POs that anything in the grey zone (which is robust reality at no-public-payline-NIDA) will be picked up because all spare change is going to the two aforementioned boondoggles.

## Your Grant In Review: Errors of fact from incompetent reviewers

Dec 03 2015 Published by under Grantsmanship, NIH, NIH Careerism

Bjoern Brembs has posted a lengthy complaint about the errors of fact made by incompetent reviewers of his grant application.

I get it. I really do. I could write a similar penetrating expose of the incompetence of reviewers on at least half of my summary statements.

And I will admit that I probably have these thoughts running through my mind on the first six or seven reads of the summary statements for my proposals.

But I'm telling you. You have to let that stuff eventually roll off you like water off the proverbial duck's back. Believe me*.

Brembs:

Had Reviewer #1 been an expert in the field, they would have recognized that in this publication there are several crucial control experiments missing, both genetic and behavioral, to draw such firm conclusions about the role of FoxP.
...
These issues are not discussed in the proposal, as we expect the reviewers to be expert peers.

Speaking for the NIH grant system only, you are an idiot if you expect this level of "expert peer" as the assigned reviewers to each and every one of your applications. I am not going to pretend to be an expert in this issue but even I can suspect that the body of work on this area does not lead each and every person who is "expert" to the same conclusion. And therefore even an expert might disagree with Brembs on what reviewers should "recognize". A less-than-expert is going to be subject to a cursory or rapid reading of related literature or, perhaps, an incomplete understanding from a prior episode of attending to the issue.

As a grant applicant, I'm sorry, but it is your job to make your interpretations clear, particularly if you know there are papers pointing in different directions in the literature.

More 'tude from the Brembster:

For the non-expert, these issues are mentioned both in our own FoxP publication and in more detail in a related blog post.
...
These issues are not discussed in the proposal, as we expect the reviewers to be expert peers. Discussing them at length on, e.g., a graduate student level, would substantially increase the length of the proposal.

These are repeated several times triumphantly as if they are some excellent sick burn. Don't think like this. First, NIH reviewers are not expected to do a lot of outside research reading your papers (or others') to apprehend the critical information needed to appreciate your proposal. Second, NIH reviewers are explicitly cautioned not to follow links to sites controlled by the applicant. DO. NOT. EXPECT. REVIEWERS. TO. READ. YOUR. BLOG! ...or your papers.

With respect to "graduate student level", it will be better for you to keep in mind that many peers who do not work directly in the narrow topic you are proposing to study have essentially a graduate student level acquaintance with your topic. Write your proposal accordingly. Draw the reader through it by the hand.

__
*Trump voice

## Scenes

In the past few weeks I have been present for the following conversation topics.

1) A tech professional working for the military complaining about some failure on the part of TSA to appropriately respect his SuperNotATerrorist pass that was supposed to let him board aircraft unmolested...unlike the the rest of us riff raff. I believe having his luggage searched in secondary was mentioned, and some other delays of minor note. This guy is maybe early thirties, very white, very distinct regional American accent, good looking, clean cut... your basic All-American dude.

2) A young guy, fresh out of the military looking to get on with one of the uniformed regional service squad types of jobs. This conversation involved his assertions that you had to be either a woman or an ethnic minority to have a shot at the limited number of jobs available in any given cycle. Much of the usual complaining about how this was unfair and it should be about "merit" and the like. Naturally this guy is white, clean cut, relatively well spoken.... perhaps not all that bright, I guess.

3) A pair of essentially the most privileged people I know- mid-adult, very smart, blonde, well educated, upper middle class, attractive, assertive, parents, rock of community type of women. Literally *everything* goes in these women's direction and has for most of their lives. They had the nerve to engage in a long running conversation about their respective minor traffic stops and tickets and how unfair it was. How the cops should have been stopping the "real" dangers to society at some other location instead of nailing them for running a stop sign a little too much or right on red-ing or whatever their minor ticket was for.

One of the great things about modern social media is that, done right, it is a relatively non-confrontational way to start to see how other people view things. For me the days of reading science blogs and the women-in-academics blogs were a more personal version of some of the coursework I enjoyed in my liberal arts undergraduate education. It put me in touch with much of the thinking and experiences of women in my approximate career. It occasionally allowed me to view life events with a different lens than I had previously.

It is my belief that social media has also been important for driving the falling dominoes of public opinion on gay marriage over the past decade or so. Facebook connections to friends, family and friends of the same provides a weekly? daily? reminder that each of us know a lot of gay folks that are important to us or at the very least are important to people that are important to us.

The relentless circulation of memes and Bingo cards, of snark and hilarity alike, remind each of us that there is a viewpoint other than our own.

And the decent people listen. Occasionally they start to see things the way other people do. At least now and again.

The so-called Black Twitter is similar in the way it penetrated the Facebook and especially Twitter timelines and daily RTs of so many non-AfricanAmerican folks . I have watched this develop during Ferguson and through BlackLivesMatter and after shooting after shooting after shooting of young black people that has occurred in the past two years.

During the three incidents that I mention, all I could think was "Wow, do you have any idea that this is the daily reality for many of your fellow citizens? And that it would hardly ever occur to non-white people to be so blindly outraged that the world should dare to treat them this way?" And "Wait, so are you saying it sucks to have a less-assured chance of gaining the career benefits you want due to the color of your skin or the nature of your dangly bits....it'll come to you in a minute".

This brings me to today's topic in academic science.

Nature News has an editorial on racial disparity in NIH grant awards. As a reminder the Ginther report was published in 2011. There are slightly new data out, generated from a FOIA request:

Pulmonologist Esteban Burchard and epidemiologist Sam Oh of the University of California, San Francisco, shared the data with Nature after obtaining them from the NIH through a request under the Freedom of Information Act. The figures show that under-represented minorities have been awarded NIH grants at 78–90% the rate of white and mixed-race applicants every year from 1985 to 2013

I will note that Burchard and Oh seem to be very interested in how the failure to include a diverse population in scientific studies may limit health care equality. So this isn't just about career disparity for these scientists, it is about their discipline and the health outcomes that result. Nevertheless, the point of these data are that under-represented minority PIs have less funding success than do white PIs. The gap has been a consistent feature of the NIH landscape through thick and thin budgets. Most importantly, it has not budged one bit in the wake of the Ginther report in 2011. With that said, I'm not entirely sure what we have learned here. The power of Ginther was that it went into tremendous analytic detail trying to rebut or explain the gross disparity with all of the usual suspect rationales. Trying....and failing. The end result of Ginther was that it was very difficult to make the basic disparate finding go away by considering other mediating variables.

After controlling for the applicant's educational background, country of origin, training, previous research awards, publication record, and employer characteristics, we find that black applicants remain 10 percentage points less likely than whites to be awarded NIH research funding.

The Ginther report used NIH grant data between FY 2000 and FY 2006. This new data set appears to run from 1985 to 2013, but of course only gives the aggregate funding success rate (i.e. the per-investigator rate), without looking at sub-groups within the under-represented minority pool. This leaves a big old door open for comments like this one:

Is it that the NIH requires people to state their race on their applications or could it be that the black applications were just not as good? Maybe if they just keep the applicant race off the paperwork they would be able to figure this out.

and this one:

I have served on many NIH study sections (peer review panels) and, with the exception of applicants with asian names, have never been aware of the race of the applicants whose grants I've reviewed. So, it is possible that I could have been biased for or against asian applicants, but not black applicants. Do other people have a different experience?

This one received an immediate smackdown with which I concur entirely:

That is strange. Usually a reviewer is at least somewhat familiar with applicants whose proposals he is reviewing, working in the same field and having attended the same conferences. Are you saying that you did not personally know any of the applicants? Black PIs are such a rarity that I find it hard to believe that a black scientist could remain anonymous among his or her peers for too long.

Back to social media. One of the tweeps who is, I think, pretty out as an underrepresented minority of science had this to say:

Not entirely sure it was in response to this Nature editorial but the sentiment fits. If AfricanAmerican PIs who are submitting grants to the NIH after the Ginther report was published in the late summer of 2011 (approximately 13 funding rounds ago, by my calendar) were expecting the kind of relief provided immediately to ESI PIs.....well, they are still looking in the mailbox.

The editorial

The big task now is to determine why racial funding disparities arise, and how to erase them. ...The NIH is working on some aspects of the issue — for instance, its National Research Mentoring Network aims to foster diversity through mentoring.

and the News piece:

in response to Kington’s 2011 paper, the NIH has allocated more than $500 million to programmes to evaluate how to attract, mentor and retain minority researchers. The agency is also studying biases that might affect peer review, and is interested in gathering data on whether a diverse workforce improves science. remind us of the entirely toothless NIH response to Ginther. It is part and parcel of the vignettes I related at the top. People of privilege simply cannot see the privileges they enjoy for what they are. Unless they are listening. Listening to the people who do not share the set of privileges under discussion. I think social media helps with that. It helps me to see things through the eyes of people who are not like me and do not have my particular constellations of privileges. I hope even certain Twitter-refuseniks will come to see this one day. ## A simple suggestion for Deputy Director for Extramural Research Lauer and CSR Director Nakamura Nov 19 2015 Published by under Fixing the NIH, NIH, NIH Careerism Michael S. Lauer, M.D., and Richard Nakamura, Ph.D. have a Perspective piece in the NEJM which is about "Reviewing Peer Review at the NIH". The motivation is captured at the end of the first paragraph: Since review scores are seen as the proximate cause of a research project's failure to obtain support, peer review has come under increasing criticism for its purported weakness in prioritizing the research that will have the most impact. The first half or more of the Perspective details how difficult it is to even define impact, how nearly impossible it is to predict in advance and ends up with a very true observation "There is a robust literature showing that expert opinion often fails to predict the future." So why proceed? Well, because On the other hand, expert opinion of past and current performance has been shown to be a robust measure; thus, peer review may be more helpful when used to assess investigators' track records and renewal grants, as is typically done for research funded by the Howard Hughes Medical Institute and the NIH intramural program. This is laughably illogical when it comes to NIH grant awards. What really predicts future performance and scientific productivity is who manages to land the grant award. The money itself facilitates the productivity. And no, they have never ever done this test I guarantee you. When have they ever handed a whole pile of grant cash to a sufficient sample of the dubiously-accomplished (but otherwise reasonably qualified) and removed most funding from a fabulously productive (and previously generously-funded) sample and looked at the outcome? But I digress. The main point comes later when the pair of NIH honchos are pondering how to, well, review the peer review at the NIH. They propose reporting broader score statistics, blinding review*, scoring renewals and new applications in separate panels and correlating scores with later outcome measures. Notice what is missing? The very basic stuff of experimental design in many areas of research that deal with human judgment and decision making. Here is my proposal for Drs. Lauer and Nakamura. Find out first if there is any problem with the reliability of review for proposals. Take an allocation of grants for a given study section and convene a parallel section with approximately the same sorts of folks. Or get really creative and split the original panels in half and fill in the rest with ad hocs. Whenever there is a SEP convened, put two or more of them together. Find out the degree to which the same grants get fundable scores. That's just the start. After that, start convening parallel study sections to, again, review the exact same pile of grants except this time change the composition to see how reviewer characteristics may affect outcome. Make women-heavy panels, URM-heavy panels, panels dominated by the smaller University affiliations and/or less-active research programs. etc. This would be a great chance to pit the review methods against each other too. They should review an identical pile of proposals in traditional face-to-face meetings versus phone-conference versus that horrible web-forum thing. Use this strategy to see how each and every aspect of the way NIH reviews grants now might contribute to similar or disparate scores. This is how you "review peer review" gentlemen. There is no point in asking if peer review predicts X, Y or Z outcome for a given grant when funded if it cannot even predict itself in terms of what will get funded. __ *And by the way, when testing out peer review, make sure to evaluate the blinding. You have to ask the reviewers to say who they think the PIs are, their level of confidence, etc. And you have to actually analyze the results intelligently. It is not enough to say "they missed most of the time" if either the erroneous or correct guesses are not randomly distributed. Additional Reading: Predicting the future In case you missed it, the Lauer version of Rock Talk is called Open Mike. Cite: Reviewing Peer Review at the NIH Michael S. Lauer, M.D., and Richard Nakamura, Ph.D. N Engl J Med 2015; 373:1893-1895November 12, 2015 DOI: 10.1056/NEJMp1507427 ## Ask DrugMonkey: JIT and Progress Reports Nov 10 2015 Published by under Ask DrugMonkey, NIH, NIH Careerism, NIH funding Two quick things: Your NIH grant Progress Report goes to Program. Your PO. It does not go to any SRO or study section members, not even for your competing renewal application. It is for the consumption of the IC that funded your grant. It forms the non-competing application for your next interval of support that has already passed competitive review muster. Second. The eRA commons automailbot sends out requests for your JIT (Just In Time; Other Support page, IRB/IACUC approvals) information within weeks of your grant receiving a score. The precise cutoff for this autobot request is unclear to me and it may vary by IC or by mechanism for all I know. The point is, that it is incredibly generous. Meaning that when you look at your score and think "that is a no-way-it-will-ever-fund score" and still get the JIT autobot request, this doesn't mean you are wrong. It means the autobot was set to email you at a very generous threshold. JIT information is also requested by the Grants Management Specialist when he/she is working on preparing your award, post-Council. DEFINITELY respond to this request. The only advantage I see to the autobot request is that if you need to finalize anything with your IRB or IACUC this gives you time. By the time the GMS requests it, you are probably going to be delaying your award if you do not have IRB/IACUC approval in hand. If you submit your Other Support page with the autobot request, you are just going to have to update it anyway after Council. ## NIH should involve the not-yet-funded in review Nov 09 2015 Published by under NIH, NIH Careerism Following up my post on RFAs and the inherent self-reinforcing conservatism of NIH grant review. ## RFAs do not narrow the NIH portfolio, quite the opposite. Nov 06 2015 Published by under Fixing the NIH, NIH, NIH Careerism Mike the Mad Biologist has taken issue with the findings of a "cross-campus, cross-career stage and cross-disciplinary series of discussions at a large public university" which "has produced a series of recommendations for addressing the problems confronting the biomedical research community in the US". Mike the Mad has pulled out a number of the proposals and findings to address but I was struck by one on the role of "R&D contracts, Requests for Applications (RFAs) and intramural research". From page 4 of the UW report: Fourth, the NIH should increase the proportion of its budget directed to Research Project Grants, Center Grants and Training, and it should decrease the proportion directed to R&D contracts, Requests for Applications (RFAs) and intramural research. These changes would redirect funds towards investigator-initiated research and allow funding of a greater diversity of projects. R&D contracts and RFAs place limits on the topics and approaches that can be pursued, so a shift away from them will lead to fewer intellectual constraints being placed on researchers. We emphasize that this is not a recommendation to eliminate R&D contracts or RFAs, but rather to reduce their number, which will sharpen their quality and provide the funds needed to award more investigator-initiated grants. I disagree with the notion that RFAs are poisonous to diversity and the notion that pure "investigator-initiated" leads to fewer intellectual constraints. The NIH peer review process is an inherently conservative one because it tends to reinforce itself. Those who are successful within the system do the primary judging of who is next to be successful. Those who become successful have to, in large degree, adapt themselves to the thinking and expectations of those who have previously been successful. When it comes to the role of Program Officers in selecting grants for pickups and saves, well, they too are influenced by the already-successful. This is in addition to the fact that POs have long term careers and thus their orientations and biases come into play across literally decades of grant applications. To the extent that POs are judged by the performance of their grant portfolios, you can see that they are no different than the rest of us. Higher JIF, higher citations, more press attention, more high-profile scientists....all of these things dictate them selecting grants that are going to be more of the same. Sure, this is a thumb on the scale. Lots of scientists are open to new ideas. Lots of scientists can become enamoured of scientific proposals that are outside of their immediate interests. Peer reviewers and Program Officers alike. But there more assuredly is a thumb on the scale. And it is a constantly reinforcing cycle of conservatism to select grants for funding that are very much like ones that have previously been funded. Alike in topic, alike in PI characteristics, alike in the University which is applying. Request for Applications (RFAs) quite often serve to fight against the narrowing of topic diversity and in favor of getting grants funded in a new area of investigation. Trust me, if they already have copious amounts of grant funding on a topic, this does not result in additional RFAs! In some of my general oversight of RFAs over the years from some of my favorite ICs I've noticed topics like sex-differences and less-usual experimental models are often at play. Adolescent/developmental studies as well. To take a shot at my much beloved NIDA--- well, they have been, and continue to be, the National Institute on Cocaine and Heroin Abuse. Notice how whenever the current Director Nora Volkow gets interviewed on the general lay media she goes on and on about the threat of marijuana to our adolescents? Try a trip over to RePORTER to review NIDA's respective portfolios on marijuana versus cocaine or heroin. There have been several NIDA RFAs, PARs and PASs over the years which are really about "Gee, can't we fund at least two grants on this other drug over here?". There's an old one begging for medications development for cannabis dependence (RFA-DA-04-014; 10 awards funded) and another asking for investigation of developmental effects of cannabis exposure (RFA-DA-04-016; 6 awards funded). Prenatal exposure to MDMA (RFA-DA-01-005). Etc. The latest version of this is PAR-14-106 on synthetic drugs. You know, the bath salts and the fake weed. I've been chatting with you about these since what, 2010? The PAR was issued in 2014 (4 awards funded so far, 5 if you include R03/R21 versions). Is this because evil NIDA wants to force everyone to start working on these topics? Constraining their intellectual freedom? Hampering the merry progress on cocaine and heroin? You might ask the same about various sex-differences FOA that have been issued over the years. Heck no. All that stuff has continued to be funded at high rates under NIDA's normal operation. Why? well because tons and tons and tons of highly funded and highly productive researchers have focused on cocaine and heroin for their entire careers. And these are the grants that seem most important to them....the cocaine and heroin grants. They are the successful scientists who review other grants and who whisper in the ears of POs at every turn. So the other drugs get short shrift in the funding race. Every now and again a PO gets up the courage to mount an assault on this conservatism and get a few grants funded in his or her bee-in-the-bonnet interest. Having watched one of these develop back in the good old days, it takes time. Two POs I observed at NIDA set up mini-symposia at NIH and at meetings for several years before lo and behold an RFA was issued on that topic. This was in the days when presumably they had the spare cash to do this sort of grooming of a topic domain. The CRAN initiative initially side-stepped the review process altogether and issued supplements for combined-drug research (think "effects of alcohol drinking on smoking behavior and vice versa"). Etc. I am sure that parallels exist at all of the other ICs. And let me be emphatically clear on this. It isn't as though there are not individual investigators out there independently initiating grant applications on these topics. OF COURSE there are. They just haven't been able to get funded. I come back to this claim in the UW document that RFAs "place limits on the topics and approaches that can be pursued" and the suggestion that their diminishment will lead to "fewer intellectual constraints being placed on researchers". This is nonsense. Targeted FOAs very often address topics which have been "investigator-initiated" many, many times but these applications have not been successful in navigating the study section process. I would be shocked if there were more than a very small number of targeted funding announcements from the NIH that were on a topic that nobody had ever applied for funding to research. Shocked. The pool of people applying for funding is just so large and so diverse that any half-way interesting idea has been proposed by somebody at some point in time. The idea that NIH Program have come up with something that nobody in the extramural community has ever thought about is just not that credible. ## NCI announces the R50 Research Specialist career award Nov 02 2015 Published by under Careerism, NIH, NIH Careerism PAR-16-025 invites applications for the R50 Research Specialist award. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to pursue research within the context of an existing cancer research program, but not serve as independent investigators. These scientists, such as researchers within a research program, core facility managers, and data scientists, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide desirable salaries and sufficient autonomy so that individuals are not solely dependent on grants held by Principal Investigators for career continuity. This mechanism is for salary support up to 100% and for travel up to$5,000 per year. Maximum duration is 5 years. It is interesting that they chose to make this an R mech instead of a K mech. I like that. A lot.

This idea was discussed by NCI a little bit ago, as discussed in this blog post, in the wake of a hint from Varmus when he left the NCI Director office. The devil will be in the detail but this new mechanism appears to leave some wiggle room for the Research Specialist to avoid some deficits I identified in the original discussion (start at 2:20).

I was most concerned about all the discussion focusing on the original PI and how this proposed new mechanism was to his or her benefit more than the Research Specialist themselves.

2:29 -the research proposal is to be written jointly by the applicant and the sponsoring PI, describing the research.

[DM- I think this is workable even though my eye started to twitch. There is going to be some slippage here with respect to the goals of making this award portable and not tied to the fate of one lab's research grant]

2:29:55 -Initially the Research Specialist to apply while supported on an existing research grant. Once the K05 is awarded, it would be expected to be 50/50 support with the grant and then continuing on the K05 100% once the grant ended.

2:30:30 - Review criteria. Accomplishment of applicant individually and within the nominating lab's program. Accomplishment of the PI and Uni. Importance of the applicant to the research program of the PI.

[DM- Welp. This is certainly going down a road of contributing to the rich getting richer which is not something I support. Unless "importance to the research program of the PI" means helping to stabilize the science of a have-not type of PI who struggles to maintain consistent funding.]

and

2:32: slide on portability of the award - possible but requires PO approval if PI and K05 move together, if the PI leaves and K05 stays, if the grant is lost, etc.

if K05 Specialist chooses on her/his own hook to leave old lab, it will require a new PI, approval, etc. The old PI is eligible for 2 year administrative supplement because they are "suddenly missing a critical support component".

[DM- ugh, this last part. Why should the original grant be compensated for the K05 person deciding to leave? It will already have benefited from that 50% free effort. Rich get richer, one. and a reward for that scenario where the PI is such a jerkface that the K05 leaves him/her? no. and regarding "critical support component", dude, what about when any postdoc chooses to leave? happens all the time. can I get some free money for suddenly missing an awesome postdoc?]

2:36 on assessment of the pilot. "critical to get input from the PI about how well their needs have been served"

[DM- well sure. but...... grrrr. this should be about the K05 awardee's perspective. The whole point is that the existing system puts these people's careers into the hands of the big cheese PI. That is what the focus should be on here. The K05 Research Specialist. Not on whether the PI's loss of control has allowed him or her to continue to exploit or whether this is just a way to shield the haves of the world from the grant game a little bit more.]

Two interesting parts of note in the section on Award Administration from this new PAR:

5) Funds freed up through the R50 will be restricted from any other personnel use, but may be rebudgeted for other research costs with NCI prior approval.

6) Research Specialists would have the option, with prior NCI approval, to move to other research programs or institutions (e.g. if the Unit Director's laboratory is closed, if the institution closes a core, etc.).

Number 5 is a bit weird. Why not be able to hire another person to work on the project? And re-budgeting is allowed only with prior approval? For a salary? This is unusual.

But everything about this rests on what Number 6 turns out to be in practice. It echos another part in the FOA scope part that reads:

The proposed new research support is intended to provide desirable salaries and sufficient autonomy so that individuals are not solely dependent on grants held by Principal Investigators for career continuity. Research Specialists would have the option, with prior NCI approval, to move to other research programs or institutions while maintaining funding from this award (e.g., if the Principal Investigator's laboratory is closed, if the institution closes a core, etc.).

This is the part that gives the Research Specialist the true "sufficient autonomy" and "not solely dependent" business that is written all throughout the PAR. It is essential how broadly this "e.g." is interpreted, particularly with respect to who makes the decisions about permitting a change. Obviously, the one major thing missing from these examples is the autonomous choice of the Research Specialist. What if she or he simply wants to join a different lab or university? How easily can it be moved to another city when the person's spouse gets a new job? How easily can they detach themselves from a toxic PI? etc.

__
h/t: @superkash

## Thought of the Day

Oct 16 2015 Published by under Grant Review, Grantsmanship, NIH, NIH Careerism

I know this NIH grant game sucks.

I do.

And I feel really pained each time I get email or Twitter messages from one of my Readers (and there are many of you, so this isn't as personal as it may seem to any given Reader) who are desperate to find the sekrit button that will make the grant dollars fall out of the hopper.

I spend soooooo much of my discussion on this blog trying to explain that NOBODY CAN TELL YOU WHERE THE SEKRIT BUTTON IS BECAUSE IT DOESN'T EXIST!!!!!!!!!!!!

Really. I believe this down to the core of my professional being.

Sometimes I think that the problem here is the just-world fallacy at work. It is just so dang difficult to give up on the notion that if you just do your job, the world will be fair. If you do good work, you will eventually get the grant funding to support it. That's what all the people you trained around seemed to experience and you are at least as good as them, better in many cases, so obviously the world owes you the same sort of outcome.

I mean yeah, we all recognize things are terrible with the budget and we expect it to be harder but.....maybe not quite this hard?

I feel it too.

Believing in a just-world is really hard to shed.

## NIH grant application changes are in the offing

Oct 16 2015 Published by under NIH, NIH Careerism, NIH funding

The Weekly NIH Guide (for 16 October 2015, that link will update) has a whole slew of changes summarized in NOT-OD-16-004.

NOT-OD-16-006 seeks to simplify the Vertebrate Animals section by deleting requirement for describing vet care, euthanasia if consistent with AVMA guidelines and justification for the number of animals used.

NOT-OD-16-011 seeks to implement rigor and transparency in grant applications. Focus is on "the scientific premise forming the basis of the proposed research, rigorous experimental design for robust and unbiased results,consideration of relevant biological variables , and authentication of key biological and/or chemical resources."

oh, and for certain people around here NOT-OD-16-009 plans a change in allowable fonts that can be used in NIH grant applications. Key features are black text, 6 lines per vertical inch, 15 characters per linear inch and 11 pt type. The usual fonts are "recommended" although "other fonts (both serif and non-serif) are acceptable if they meet the above requirements"

• Scientopia Blogs

• DrugMonkey is an NIH-funded researcher who blogs about careerism in science. And occasionally about the science of drug use.

• Your donation helps to support the operation of Scientopia - thanks for your consideration.